143527-76-8

Basic information

• Product Name: 13-{[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl}-10-deacetyl-7,10-bis{[(2,2,2-trichloroethyl)oxy]carbonyl} Baccatin III
• Synonyms: 13-{[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl}-10-deacetyl-7,10-bis{[(2,2,2-trichloroethyl)oxy]carbonyl} Baccatin III;(4S,5R)-2,2-DiMethyl-4-phenyl-3,5-oxazolidinedicarboxylic Acid 5-[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetraMethyl-5-oxo-4,6-bis[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl] 3-(1,1-diMethylethyl) Ester;LLLJXWNWAFHRTB-CHFAFVNJSA-N
• CAS NO: 143527-76-8
• Molecular Formula: C₅₂H₅₉Cl₆NO₁₈
• Molecular Weight: 1198.73876
• Product Categories: Intermediates & Fine Chemicals;Metabolites;Pharmaceuticals;Metabolites, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 143527-76-8.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Solubility: Chloroform, Ethyl Acetate
• CAS DataBase Reference: 13-{[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl}-10-deacetyl-7,10-bis{[(2,2,2-trichloroethyl)oxy]carbonyl} Baccatin III(CAS DataBase Reference)
• NIST Chemistry Reference: 13-{[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl}-10-deacetyl-7,10-bis{[(2,2,2-trichloroethyl)oxy]carbonyl} Baccatin III(143527-76-8)
• EPA Substance Registry System: 13-{[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl}-10-deacetyl-7,10-bis{[(2,2,2-trichloroethyl)oxy]carbonyl} Baccatin III(143527-76-8)

Safety Data

• Hazardous Substances Data: 143527-76-8(Hazardous Substances Data)

Usage

Description

13-[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl-10-deacetyl-7,10-bis[(2,2,2-trichloroethyl)oxy]carbonyl Baccatin III is a complex organic compound that serves as an intermediate in the synthesis of a metabolite of Docetaxel, an antineoplastic agent. It is characterized by its white solid appearance and plays a crucial role in the pharmaceutical industry due to its potential applications in cancer treatment.

Uses

Used in Pharmaceutical Industry:
13-[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl-10-deacetyl-7,10-bis[(2,2,2-trichloroethyl)oxy]carbonyl Baccatin III is used as an intermediate in the synthesis of Docetaxel metabolites for its antineoplastic properties. 13-[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl-10-deacetyl-7,10-bis[(2,2,2-trichloroethyl)oxy]carbonyl Baccatin III contributes to the development of cancer treatments by enhancing the effectiveness of chemotherapy and potentially improving patient outcomes.
Used in Anticancer Applications:
As an intermediate in the synthesis of Docetaxel metabolites, 13-[(3-N-Boc)-2,2-dimethyl-4S-phenyl-1,3-oxazolidin-5R-yl]formyl-10-deacetyl-7,10-bis[(2,2,2-trichloroethyl)oxy]carbonyl Baccatin III plays a significant role in the development of anticancer drugs. It aids in the creation of medications that target and inhibit the growth of cancer cells, offering a promising avenue for cancer treatment and management.
Used in Drug Delivery Systems:
The compound may also be utilized in the development of novel drug delivery systems, aiming to improve the bioavailability and therapeutic outcomes of Docetaxel and its metabolites. By employing various organic and metallic nanoparticles as carriers, the compound can enhance the delivery and efficacy of antineoplastic agents, potentially leading to better treatment options for cancer patients.

Upstream product

• 95603-44-4 7,10-di-(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III 
• 143615-03-6 (4S,5R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 143615-00-3 (2R,3S)-3-amino-3-phenyl-2-hydroxypropionic acid ethyl ester 
• 144787-20-2 (2R,3S)-3-azido-2-hydroxy-benzenepropanoic acid ethyl ester 
• 100-52-7 benzaldehyde 
• 126060-73-9 ethyl (2R,3R)-3-phenyl-2,3-oxiranepropanoate 
• 143527-75-7 (2R,3S) ethyl N-(t-butoxycarbonyl)-3-phenylisoserine 
• 143527-74-6 ethyl (4S,5R)-3-tert-butoxycarbonyl-2,2-dimethyl-4-phenyl-5-oxazolidinecarboxylate 
• 144704-63-2 (4S,5R)-3-((2S,3R)-2-Bromo-3-hydroxy-3-phenyl-propionyl)-4-methyl-5-phenyl-oxazolidin-2-one 
• 32981-86-5 10-deacetylbaccatin III 

Downstream Products

• 114915-16-1 10-deacetyl-7,10-diTroc-baccatin III 
• 159262-93-8 10-deacetylbaccatin III-13-O-[(4S,5R)-4-phenyl-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidine-5-carboxylate] 
• 162552-56-9 C₄₆H₅₆INO₁₃ 
• 159262-92-7 C₄₇H₅₆F₃NO₁₆S 
• 114915-20-7 Docetaxel 
• 114915-14-9 7,10-bis-O-(2,2,2-trichloroethoxycarbonyl)docetaxel 
• 114915-18-3 C₅₁H₅₁Cl₆NO₁₇ 

Relevant articles and documents

Method for purifying docetaxel

The invention discloses a method for purifying docetaxel. A docetaxel solid precipitates from a dichloromethane and toluene mixed solution. The purifying method has the advantages of great reduction of the single content of every impurity in docetaxel, introduction of few impurities, improvement of the purity of the product, and high yield, and is very suitable for industrial large-scale production, and the obtained product meets preparation demands, and can be directly used to prepare a docetaxel injection.

Alternative synthesis and the determination of absolute configuration of docetaxel, an anticancer drug

A simple, efficient, and alternative synthetic route for docetaxel with better control on the protection-deprotection sequence has been developed. The process is easily scalable and commercially viable, and critical impurities can be controlled efficiently. For the first time, absolute configuration of docetaxel was determined unambiguously by single-crystal X-ray diffraction.

PREPARATION OF DOCETAXEL

The present invention relates to docetaxel and processes for preparing docetaxel, including process-related intermediates. The present invention also relates to processes for preparing substantially pure docetaxel and intermediates.